Ariella L G Coler-Reilly

List of Publications by Year
in descending order

25	1,227	516561 16	610775 24
papers	citations	h-index	g-index

27	27	27	1899
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The complement system in COVID-19: friend and foe?. JCI Insight, 2020, 5, .	2.3	295
2	Hope on the Horizon: Novel Fungal Treatments in Development. Open Forum Infectious Diseases, 2020, 7, ofaa016.	0.4	139
3	HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. Journal of Clinical Investigation, 2014, 124, 3431-3442.	3.9	100
4	CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. PLoS Neglected Tropical Diseases, 2013, 7, e2479.	1.3	91
5	Mogamulizumab (Anti-CCR4) in HTLV-1â€“Associated Myelopathy. New England Journal of Medicine, 2018, 378, 529-538.	13.9	79
6	Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain, 2013, 136, 2876-2887.	3.7	75
7	Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin. Human Cell, 2013, 26, 8-18.	1.2	61
8	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Review of Clinical Immunology, 2020, 16, 659-666.	1.3	57
9	Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Frontiers in Microbiology, 2018, 9, 1651.	1.5	48
10	HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells that produces an inflammatory positive feedback loop via astrocytes in HAM/TSP. Journal of Neuroimmunology, 2017, 304, 51-55.	1.1	42
11	Mogamulizumab, an Anti-CCR4 Antibody, Targets Human T-Lymphotropic Virus Type 1â€“infected CD8⁺and CD4⁺T Cells to Treat Associated Myelopathy. Journal of Infectious Diseases, 2015, 211, 238-248.	1.9	37
12	Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). Orphanet Journal of Rare Diseases, 2016, 11, 69.	1.2	33
13	Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort Study. Neurotherapeutics, 2017, 14, 1084-1094.	2.1	29
14	Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1â€“associated myelopathy/tropical spastic paraparesis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11685-11691.	3.3	28
15	Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. Orphanet Journal of Rare Diseases, 2019, 14, 227.	1.2	21
16	Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions. Medicine (United States), 2017, 96, e6021.	0.4	20
17	Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Frontiers in Microbiology, 2019, 10, 2110.	1.5	17
18	Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P). Viruses, 2022, 14, 136.	1.5	15

#	Article	IF	Citations
19	RAISING is a high-performance method for identifying random transgene integration sites. Communications Biology, 2022, 5, .	2.0	12
20	Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 321-323.	0.9	11
21	Liquid Crystal Gel Reduces Age Spots by Promoting Skin Turnover. Cosmetics, 2014, 1, 202-210.	1.5	4
22	Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet Journal of Rare Diseases, 2020, 15, 175.	1.2	4
23	Patient satisfaction survey for HAM-net registrants. Retrovirology, 2015, 12, .	0.9	1
24	Positive feedback loop through astrocytes causes chronic inflammation in human Tâ€lymphotropic virus type 1â€associated myelopathy/tropical spastic paraparesis. Clinical and Experimental Neuroimmunology, 2014, 5, 108-109.	0.5	0
25	Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy. Frontiers in Medicine, 2022, 9, 879379.	1.2	0